Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2001-3-14
pubmed:abstractText
In this study, we investigated whether recombinant human growth hormone (rhGH) influences the progression of myocarditis. We induced experimental autoimmune myocarditis in F344 rats by subcutaneous injection of cardiac myosin, and divided the rats into three groups: (1) control group, saline injection; (2) pre-treated group, subcutaneous injection of rhGH (100 mIU/rat/day for 10 days) before induction of experimental autoimmune myocarditis; and (3) post-treated group, subcutaneous injection of rhGH (100 mIU/rat/day for 10 days) after induction of experimental autoimmune myocarditis. On the 35th day after induction of experimental autoimmune myocarditis, all rats were sacrificed and the hearts were examined. The increase in body weight was smaller in the control group than the pre-treated group and the rate of heart weight/body weight was larger in the control group than in the two treated groups. Histopathologically, rats in the control group showed multifocal infiltration by inflammatory cells, mainly neutrophils, lymphocytes and macrophages, extensive fibrosis, and a higher proportion of mast cells in the inflamed region. In contrast, rats in the two treated groups showed only minor changes. We found that rhGH did not influence the distribution of lymphocytes in peripheral blood in the three groups, and that rhGH induced G1 checkpoint dysfunction, thereby arresting the cell cycle in G1 and inhibiting the proliferation of mast cells in vitro. These findings suggest a possible role for mast cells in the progression of myocarditis and the rhGH may be a candidate for use as a new tool to treat myocarditis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0014-2999
pubmed:author
pubmed:issnType
Print
pubmed:day
9
pubmed:volume
415
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
51-60
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:11245852-Animals, pubmed-meshheading:11245852-Antigens, CD4, pubmed-meshheading:11245852-Antigens, CD45, pubmed-meshheading:11245852-Antigens, CD8, pubmed-meshheading:11245852-Body Weight, pubmed-meshheading:11245852-Cell Cycle, pubmed-meshheading:11245852-Cell Division, pubmed-meshheading:11245852-Cell Line, pubmed-meshheading:11245852-Disease Progression, pubmed-meshheading:11245852-Dose-Response Relationship, Drug, pubmed-meshheading:11245852-G1 Phase, pubmed-meshheading:11245852-Human Growth Hormone, pubmed-meshheading:11245852-Humans, pubmed-meshheading:11245852-Immunophenotyping, pubmed-meshheading:11245852-Lymphocytes, pubmed-meshheading:11245852-Male, pubmed-meshheading:11245852-Myocarditis, pubmed-meshheading:11245852-Myocardium, pubmed-meshheading:11245852-Organ Size, pubmed-meshheading:11245852-Rats, pubmed-meshheading:11245852-Rats, Inbred F344, pubmed-meshheading:11245852-Recombinant Proteins, pubmed-meshheading:11245852-Specific Pathogen-Free Organisms
pubmed:year
2001
pubmed:articleTitle
Growth hormone interferes with the progression of myocarditis in rats.
pubmed:affiliation
Division of Basic Science, Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan. zong3961@kanazawa-med.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't